Entering the import and export business for medical equipment
First written in FY2016. 7 of 21 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-08-12.
No other company in this theme has enough history to compare yet.
- FY2021-Q1DroppedAnnual report
「Through the end of the previous consolidated fiscal year, 株式会社エクソーラメディカル continued preparations under the Import and Sales Business segment to introduce a breath-based breast cancer testing device in Japan. However, because the expected testing performance could not be achieved, the company determined at the end of the previous consolidated fiscal year that it would be difficult to continue business activities aimed at introducing the device in Japan. Accordingly, the Import and Sales Business segment has been excluded from the first quarter of the current consolidated cumulative period.」
Because the expected testing performance could not be achieved for the breath-based breast cancer screening device and continuing activities aimed at introducing it in Japan was deemed difficult, the import and sales business segment was excluded from the segment disclosures beginning this quarter. - FY2020WorsenedAnnual report
「Because the expected testing performance could not be achieved, the company determined that it would be difficult to continue business activities aimed at introducing the product in Japan. The resulting provision for doubtful accounts on financial assets was recorded in selling, general and administrative expenses, significantly affecting operating profit.」
For the breath-based breast cancer screening device, the expected testing performance could not be achieved, and it was determined that continuing activities aimed at introducing it in Japan would be difficult. A ¥353 million allowance for doubtful accounts was recognized, and the operating loss in the import and sales business widened from ¥91 million in the previous fiscal year to ¥396 million, leading to a policy of significantly scaling back the business. - FY2020-Q3WorsenedAnnual report
「The company continued preparations to introduce a breath-based breast cancer testing device in Japan. However, because the domestic launch was delayed beyond the initial expectations, it recognized an allowance for doubtful accounts of ¥257 million against financial assets recorded in the Import and Sales Business and recorded an equal amount as a provision for doubtful accounts in selling, general and administrative expenses. As a result, the business recorded an operating loss of ¥295 million, compared with an operating loss of ¥59 million in the same period of the previous year.」
The delay in introducing the breath-based breast cancer screening device in Japan continued, and a ¥257 million allowance for doubtful accounts was recognized. The operating loss widened from ¥59 million in the same period of the previous year to ¥295 million. - FY2020-Q2WorsenedAnnual report
「The company continued preparations to introduce a breath-based breast cancer testing device in Japan, but the planned domestic launch was delayed beyond the initial expectations due to delays in verification work. A review of the launch schedule at that point revealed that additional time would be required, with a launch expected around 2022. Accordingly, the company recognized an allowance for doubtful accounts of ¥257 million against financial assets recorded in the Import and Sales Business and recorded an equal amount as a provision for doubtful accounts in selling, general and administrative expenses. As a result, the business recorded an operating loss of ¥282 million, compared with an operating loss of ¥38 million in the same period of the previous year.」
The domestic introduction of a breath-based breast cancer screening device was delayed because of delays in verification work, and the start of sales was expected around 2022. A ¥257 million allowance for doubtful accounts on financial assets was recognized, causing the operating loss to widen from ¥38 million in the same period of the previous year to ¥282 million. - FY2020-Q1MitigatedAnnual report
「The Import and Sales Business incurred start-up costs associated with launching the business. As a result, the business recorded an operating loss of ¥15 million, compared with an operating loss of ¥33 million in the same period of the previous year.」
Although start-up costs associated with launching the business continued, the operating loss narrowed from ¥33 million in the same period of the previous year to ¥15 million. - FY2019WorsenedAnnual report
「The Import and Sales Business continued to incur start-up costs related to new businesses, including clinical trials at university hospitals. As a result, the business recorded an operating loss of ¥91 million, compared with an operating loss of ¥27 million in the previous fiscal year.」
Start-up costs related to new businesses, including clinical trials at university hospitals, continued, and the operating loss widened from ¥27 million in the previous fiscal year to ¥91 million. - FY2019-Q3Operating loss in the import and sales business widenedAnnual report
「The Import and Sales Business continued to incur start-up costs associated with launching the business. As a result, the business recorded an operating loss of ¥59 million, compared with an operating loss of ¥16 million in the same period of the previous year.」
Start-up costs associated with launching the business continued, and the operating loss widened from ¥16 million in the same period of the previous year to ¥59 million. - FY2019-Q2Operating loss in the import and sales business widenedAnnual report
「The Import and Sales Business continued to incur start-up costs associated with launching the business. As a result, the business recorded an operating loss of ¥38 million, compared with an operating loss of ¥9 million in the same period of the previous year.」
Start-up costs associated with launching the business continued, and the operating loss widened from ¥9 million in the same period of the previous year to ¥38 million. - FY2019-Q1Operating loss in the import and sales business widenedAnnual report
「The Import and Sales Business continued to incur start-up costs associated with launching the business. As a result, the business recorded an operating loss of ¥33 million, compared with an operating loss of ¥4 million in the same period of the previous year.」
Start-up costs associated with launching the business continued, and the operating loss widened from ¥4 million in the same period of the previous year to ¥33 million. - FY2018Operating loss widened and sales recognition beganAnnual report
「The Import and Sales Business continued to incur start-up costs associated with launching the business. As a result, the business recorded an operating loss of ¥27 million, compared with an operating loss of ¥20 million in the previous fiscal year.」
Start-up costs for the import and sales business continued, and the operating loss widened from ¥20 million in the previous fiscal year to ¥27 million. Meanwhile, sales recognition began in the third quarter for activity as the exclusive distributor in Japan for medical simulator robots. - FY2018-Q3AdvancedAnnual report
「Start-up costs continued to be incurred as the import and sales business was launched. As a result, the business recorded an operating loss of ¥16 million, compared with an operating loss of ¥13 million in the same period of the previous year. In addition, activity as the exclusive distributor in Japan for medical simulator robots by group company 株式会社エクソーラメディカル began generating results from the third quarter, although its contribution to results remained limited.」
Activity as the exclusive distributor in Japan for medical simulator robots began generating results from the third quarter. Meanwhile, the operating loss in the import and sales business widened from ¥13 million in the same period of the previous year to ¥16 million. - FY2018-Q2AdvancedAnnual report
「Although the business has yet to contribute to results, the company began operating as the exclusive distributor in Japan for medical simulator robots, using the medical device manufacturing and marketing licence held by group company 株式会社エクソーラメディカル.」
Using the medical device manufacturing and marketing licence held by エクソーラメディカル, the company began operating as the exclusive domestic distributor of medical simulator robots. - FY2018-Q1RestatedAnnual report
「The Import and Sales Business incurred start-up costs associated with launching the business. As a result, the business recorded an operating loss of ¥4 million, compared with an operating loss of ¥4 million in the same period of the previous year.」
Start-up costs and operating losses associated with launching the import and sales business continued, with the operating loss at ¥4 million, unchanged from the same period of the previous year. - FY2017RestatedAnnual report
「The Import and Sales Business incurred start-up costs associated with launching the business. As a result, the business recorded an operating loss of ¥20 million.」
The disclosure states that start-up costs and operating losses associated with launching the import and sales business continued to be incurred for the full fiscal year. - FY2017-Q3Operating loss widenedAnnual report
「The Import and Sales Business incurred start-up costs associated with launching the business. As a result, the business recorded an operating loss of ¥13 million.」
As the launch of the import and sales business continued and start-up costs were incurred, the operating loss widened from ¥9 million for the cumulative period through the previous quarter to ¥13 million. - FY2017-Q2AdvancedAnnual report
「The Import and Sales Business incurred start-up costs associated with launching the business. As a result, the business recorded an operating loss of ¥9 million.」
The launch of the import and sales business progressed, resulting in the recognition of ¥9 million in start-up costs and an operating loss. - FY2017-Q1AdvancedAnnual report
「株式会社エクソーラメディカル, which was an unconsolidated subsidiary in the previous consolidated fiscal year, has been included in the scope of consolidation from the first quarter of the current consolidated fiscal year because its materiality increased.」
エクソーラメディカル, established to import and sell medical devices, was transferred from an unconsolidated subsidiary to the scope of consolidation as its significance increased. - FY2016First statedAnnual report
「January 2016: Established 株式会社エクソーラメディカル to import and sell medical devices.」
Established a company to import and sell medical devices. Because its scale remained small after establishment, it was excluded from the scope of consolidation for the fiscal year.